Anti-infectives targeting Gram-negative 'superbugs'
|
- Detailed Technology Description
- New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics demonstrate superior efficacy and toxicity over current polymyxin antibiotics.
- *Abstract
-
New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. These novel lipopeptide antibiotics have demonstrated superior in vivo efficacy and toxicity over the currently used polymyxin antibiotics. Monash is now seeking a partner to further develop its novel lipopeptide anti-infectives.
• Novel lipopeptide antibiotics that target multidrug-resistant Gram-negative bacteria
• Greater efficacy and significantly less nephrotoxicity in animal models than currently available polymyxin B and colistin
• Potential for administration via intravenous, inhaled or topical routes.
- Country/Region
- USA
For more information, please click Here
